Determinants of HPV vaccine hesitancy and acceptance: a comparative cross-sectional analysis of Ukrainian and international cohorts
Abstract
Background. Human papillomavirus (HPV) vaccination is essential for global cervical cancer elimination. Yet, cultural, educational, and informational barriers continue to drive vaccine hesitancy, significantly limiting immunization coverage. We aimed to identify the main determinants of HPV vaccine hesitancy and acceptance by comparing awareness levels, subjective barriers, and vaccination willingness across Ukrainian and international cohorts. Methods. We distributed an anonymous online cross-sectional survey between January and February 2026, gathering responses from 365 women (293 from Ukraine and 72 from 12 other nations). The tool evaluated baseline HPV knowledge, information channels, cervical screening history, subjective obstacles, and readiness to vaccinate. Data analysis involved descriptive statistics, Pearson’s χ² tests, and multivariable binary logistic regression (оdds ratios (OR), 95% confidence interval (CI)). Results. General HPV awareness was notably higher in the Ukrainian group than in the international sample (88.7 vs 65.3%; p <0.001), as was the understanding of gender-neutral vaccination (67.6 vs 48.6%; p=0.002). Interestingly, even with better knowledge, Ukrainian women most often cited the fear of side effects as their primary barrier (39.2%). Conversely, international respondents frequently reported having no barriers at all (36.1%, p <0.001). Logistic regression confirmed that specific subjective concerns strongly predicted hesitancy. Specifically, fearing side effects increased the odds of vaccine refusal by 2.53 times (OR=2.53; 95% CI 1.21–5.29; p=0.014). Furthermore, the lack of a proactive recommendation from a physician nearly doubled the likelihood of refusal (OR=1.98; 95% CI 1.08–3.63; p=0.028). Conclusions. High theoretical awareness does not inherently translate into vaccine acceptance. Targeted public health interventions prioritizing the debunking of safety myths and fostering proactive physician recommendations are more critical for overcoming HPV vaccine hesitancy than broad awareness campaigns alone.